CEDAR – Sponsored by AllerganCompleted Study | Duration: 104 weeks
CEDAR was a multi-center, prospective, randomized Phase III clinical trial for the treatment of wet Age-Related Macular Degeneration (wet AMD). It compared the efficacy of intravitreal Abicipar Pegol vs. intravitreal Lucentis®. Abicipar Pegol is a new type of anti-VEGF drug with a long half-life and high potency towards all subtypes of VEGF-A, potentially extending intravitreal injections to once every 12 weeks and producing better outcomes. This trial was for patients with newly diagnosed wet AMD who had received no prior anti-VEGF treatment.
Participants were treated and followed for 104 weeks.